

Summary Document for Interim Clinical Considerations

for Use of COVID-19 Vaccines Currently Authorized in the United States



	Pfizer-BioNTech	Moderna	Janssen
Vaccine type	mRNA	mRNA	Replication-incompetent adenovirus type 26 vector
Authorized age groups	≥16 years	≥18 years	≥18 years
Dose	30 µg	100 µg	5×10 ¹⁰ viral particles
Dose volume	0.3 ml	0.5 ml	0.5 ml
Number of doses in series	2	2	1
Interval between doses	3 weeks (21 days)	1 month (28 days)	N/A

All currently authorized COVID-19 vaccines

Interchangeability of Vaccines	<ul style="list-style-type: none"> Vaccines are not interchangeable. However, in exceptional situations, such as a contraindication to a second dose of mRNA vaccine, interchangeability may be allowed.*
Interval between COVID-19 and other (non-COVID-19) vaccines	<ul style="list-style-type: none"> 14 days. However, COVID-19 and other vaccines may be administered in a shorter period in urgent situations such as a tetanus-toxoid containing vaccine for after wound management, or to vaccinate residents of long-term care facilities to avoid delays to COVID-19 vaccination.
Persons with prior or current COVID-19	<ul style="list-style-type: none"> COVID-19 vaccines can be given safely to people with prior SARS-CoV-2 infection Defer vaccination until person has recovered from the acute illness and criteria have been met for them to discontinue isolation While vaccine supply remains limited, persons may choose to temporarily delay vaccination due to low risk of reinfection in the months after initial infection
Persons who received monoclonal antibodies or convalescent plasma for COVID-19 treatment	<ul style="list-style-type: none"> Defer vaccination for at least 90 days
Persons with a known SARS-CoV-2 exposure	<ul style="list-style-type: none"> Persons in community or outpatient setting should defer vaccination until quarantine period has ended Residents or patients in congregate settings may be vaccinated if they do not have symptoms consistent with COVID-19
Persons with underlying conditions	<ul style="list-style-type: none"> May receive COVID-19 vaccine (including persons with immunocompromising conditions; autoimmune conditions; and history of Guillain-Barré syndrome, Bell's palsy, and dermal filler use)
Pregnant or lactating people	<ul style="list-style-type: none"> May choose to be vaccinated
Adolescents	<ul style="list-style-type: none"> Adolescents aged 18 years and older are eligible for all COVID-19 vaccines Adolescents aged 16-17 are ONLY eligible for Pfizer-BioNTech COVID-19 vaccines
Contraindications	<ul style="list-style-type: none"> Severe allergic reaction (e.g., anaphylaxis) after a previous dose or to component of the COVID-19 vaccine Immediate allergic reaction of any severity to a previous dose or known (diagnosed) allergy to a component of the vaccine
Precaution	<ul style="list-style-type: none"> Immediate allergic reaction to any other vaccine or injectable therapy (i.e., intramuscular, intravenous, or subcutaneous vaccines or therapies [excluding subcutaneous immunotherapy for allergies, i.e., "allergy shots"])
Post-vaccination observation periods	<ul style="list-style-type: none"> 30 minutes: persons with a precaution to vaccination (i.e., history of an immediate allergic reaction of any severity to a vaccine or injectable therapy) and persons with a history of anaphylaxis due to any cause 15 minutes: all other persons
SARS-CoV-2 antibody testing	<ul style="list-style-type: none"> Antibody testing not recommended for vaccine decision-making or to assess immunity following vaccination

*Although CDC provides considerations for a [mixed series in exceptional circumstances](#), this is still considered an administration error that requires VAERS reporting